| Abstract | Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of > or =75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis. |
| Authors | J C Prinz
(Affiliation: Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München. joerg.prinz at lrz.uni-muenchen.de)
|
| Journal | Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
(Hautarzt)
Vol. 56
Issue 9
Pg. 812-8
(Sep 2005)
ISSN: 0017-8470 Germany |
| Vernacular Title | Efalizumab. Dauertherapie der Psoriasis. |
| PMID | 16096737
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
- Antibodies, Monoclonal
- Dermatologic Agents
- efalizumab
|
| Topics |
- Antibodies, Monoclonal
(administration & dosage)
- Chronic Disease
- Clinical Trials as Topic
- Dermatologic Agents
(administration & dosage)
- Humans
- Physician's Practice Patterns
- Practice Guidelines as Topic
- Prognosis
- Psoriasis
(drug therapy, epidemiology)
- Treatment Outcome
|
